|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jiang L, Zhao X, Meng X and Yu J: Involved
field irradiation for the treatment of esophageal cancer: Is it
better than elective nodal irradiation. Cancer Lett. 357:69–74.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
McK Manson J and Beasley W: A personal
perspective on controversies in the surgical management of
oesophageal cancer. Ann R Coll Surg Engl. 96:575–578. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Baba Y, Watanabe M, Yoshida N and Baba H:
Neoadjuvant treatment for esophageal squamous cell carcinoma. World
J Gastrointest Oncol. 6:121–128. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Napier KJ, Scheerer M and Misra S:
Esophageal cancer: A Review of epidemiology, pathogenesis, staging
workup and treatment modalities. World J Gastrointest Oncol.
6:112–120. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ling N, Ying SY, Ueno N, Shimasaki S, Esch
F, Hotta M and Guillemin R: A homodimer of the beta-subunits of
inhibin A stimulates the secretion of pituitary follicle
stimulating hormone. Biochem Biophys Res Commun. 138:1129–1137.
1986. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lin HS, Gong JN, Su R, et al: miR-199a-5p
inhibits monocyte/macrophage differentiation by targeting the
activin A type 1B receptor gene and finally reducing C/EBPα
expression. J Leukoc Biol. 96:1023–1035. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kariyawasam HH, Semitekolou M, Robinson DS
and Xanthou G: Activin-A: a novel critical regulator of allergic
asthma. Clin Exp Allergy. 41:1505–1514. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Maeshima A, Miya M, Mishima K, Yamashita
S, Kojima I and Nojima Y: Activin A: autocrine regulator of kidney
development and repair. Endocr J. 55:1–9. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xu J, Oakley J and McGee EA:
Stage-specific expression of Smad2 and Smad3 during
folliculogenesis. Biol Reprod. 66:1571–1578. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zalzman M, Anker-Kitai L and Efrat S:
Differentiation of human liver-derived, insulin-producing cells
toward the beta-cell phenotype. Diabetes. 54:2568–2575. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ferreira MC, Witz CA, Hammes LS, Kirma N,
Petraglia F, Schenken RS and Reis FM: Activin A increases
invasiveness of endometrial cells in an in vitro model of
human peritoneum. Mol Hum Reprod. 14:301–307. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schwall RH, Robbins K, Jardieu P, Chang L,
Lai C and Terrell TG: Activin induces cell death in hepatocytes
in vivo and in vitro. Hepatology. 18:347–356. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Thissen JP and Loumaye A: Role of activin
A and myostatin in cancer cachexia. Ann Endocrinol (Paris).
74:79–81. 2013.(In French). View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hoda MA, Münzker J, Ghanim B, Schelch K,
Klikovits T, Laszlo V, Sahin E, Bedeir A, Lackner A, Dome B, et al:
Suppression of activin A signals inhibits growth of malignant
pleural mesothelioma cells. Br J Cancer. 107:1978–1986. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hofland J, van Weerden WM, Steenbergen J,
Dits NF, Jenster G and de Jong FH: Activin A stimulates AKR1C3
expression and growth in human prostate cancer. Endocrinology.
153:5726–5734. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim YI, Kim BH, Khang I, Cho BN and Lee
HK: Cell growth regulation through apoptosis by activin in human
gastric cancer SNU-16 cell lines. Oncol Rep. 21:491–497.
2009.PubMed/NCBI
|
|
18
|
Wang G, Wang L, Sun S, Wu J and Wang Q:
Quantitative measurement of serum microRNA-21 expression in
relation to breast cancer metastasis in Chinese females. Ann Lab
Med. 35:226–232. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gold E and Risbridger G: Activins and
activin antagonists in the prostate and prostate cancer. Mol Cell
Endocrinol. 359:107–112. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang Y, Bao YL, Yang MT, Wu Y, Yu CL,
Huang YX, Sun Y, Zheng LH and Li YX: Activin A induces SLC5A8
expression through the Smad3 signaling pathway in human colon
cancer RKO cells. Int J Biochem Cell Biol. 42:1964–1972. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
de Kretser DM, O'Hehir RE, Hardy CL and
Hedger MP: The roles of activin A and its binding protein,
follistatin, in inflammation and tissue repair. Mol Cell
Endocrinol. 359:101–106. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yoshinaga K, Yamashita K, Mimori K, Tanaka
F, Inoue H and Mori M: Activin a causes cancer cell aggressiveness
in esophageal squamous cell carcinoma cells. Ann Surg Oncol.
15:96–103. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yoshinaga K, Mimori K, Yamashita K,
Utsunomiya T, Inoue H and Mori M: Clinical significance of the
expression of activin A in esophageal carcinoma. Int J Oncol.
22:75–80. 2003.PubMed/NCBI
|
|
24
|
Liu SG, Li HC, Zhao BS and Cao F:
Expression of activin A in tissue and serum of patients with
esophageal squamous cell carcinoma and its clinical significance.
Zhonghua Zhong Liu Za Zhi. 35:843–847. 2013.(In Chinese).
PubMed/NCBI
|
|
25
|
Zhang C, Wang QT, Liu H, et al:
Advancement and prospects of tumor gene therapy. Chin J Cancer.
30:182–188. 2011. View Article : Google Scholar : PubMed/NCBI
|
